BCG048 / Biocytogen - LARVOL DELTA

BCG048, a novel bispecific dual-payload ADC targeting ITGB6 and B7H3, exhibited potent efficacy in patient-derived tumor xenograft models (AACR 2026) - "Additionally, BCG048 has the potential to overcome primary resistance and delay the acquisition of resistance, ultimately enhancing efficacy in heterogeneous tumors. Further studies will be necessary to evaluate its efficacy and safety in preclinical and clinical settings."

ADC • Bispecific • Late-breaking abstract • Preclinical • Bladder Cancer • Esophageal Cancer • Head and Neck Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • CD276 • ITGB6